Uncategorized

Vistagen in freefall as social anxiety drug fails Phase 3

Published

on

Despite the late-stage fail, Vistagen will nevertheless continue to push its drug candidate forward and meet with the FDA to align on a potential registrational path.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version